Compare Boston Scientific Corporation (BSX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Prospect Capital Corporation — how do they compare? Boston Scientific Corporation trades at $51.13 (market cap $71.46B), while Prospect Capital Corporation trades at $2.27 (market cap $1.15B). The key difference: Boston Scientific Corporation is far larger — about 62.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.83% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PSEC | |
|---|---|---|
Market Cap | $71.46B | $1.15B |
Sector | Health | Financials |
52-Week High | $108.14 | $3.05 |
52-Week Low | $42.63 | $2.11 |
Enterprise Value | $83.55B | — |
Dividend Yield | — | 21.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
PSEC trades at $2.33, up 5.43% in the last session, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals, with a low P/B of 0.4 and recent quarterly EPS beats, but negative revenue and net income in 2025. Recent news highlights a dividend increase for an affiliate fund and the sale of Valley Electric for a 4.8x return.
Outlook is cautious; the stock offers value with a low P/B and dividend yield, but significant risks include persistent negative profitability, high P/S ratio, and analyst skepticism. Investment appeal hinges on portfolio turnaround and sustained dividend stability amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
